retatrutide phase 3 results october 2025 New data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Retatrutide Phase 3 Updates: Significant

Nature Medicine, 30(6), 1639-1647

Phase 2: Published in the New England Journal of Medicine

Electrolyte supplementation becomes more important at higher doses, but establishing the habit now prevents problems later

That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination

In 1983, it was found to be a cleavage product of proglucagon processing and secreted by intestinal epithelial endocrine L cells (17)

doi: 10.1152/physrev.00034.2015